Effects of Albendazole therapy on liver hydatid cysts

Study of the effects of Albendazole therapy(before surgery) on viability of protoscolex

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090124001581N3

Enrollment

100

Registered

2018-04-24

Start date

2015-09-02

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Hydatid Cysts. Echinococcus granulosus infection of liver

Interventions

Intervention 1: There is no drug administration for control group. Intervention 2: administration of Albendazole 1.5 mg/kg/day for a period of7 days for intervention group2.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with liver hydatid cyst patients who have not calcified cyst patients with liver hydatid cysts that are not connected with billiary tract patients who have not infected hydatid cyst

Exclusion criteria

Exclusion criteria: patients who do not want to participate in the study patients who have contraindication for use of albendazole patients with abdominal and extra hepatic hydatis cyst patients with infected hydatid cyst patients with hydatid cyst that are connected with biliary tracts patients with calcified hydatis cyst

Design outcomes

Primary

Measure	Time frame
Scolex viability. Timepoint: After intervention. Method of measurement: Permeability method with eosin.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Reza Motie

Mashhad University of Medical Sciences

motiem@mums.ac.ir+98 51 3802 2664

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026